NCT03867253: A trial that was reported late by Oryzon Genomics S.A.
This trial has reported, although it was 879 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03867253 |
|---|---|
| Title | A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 16, 2019 |
| Completion date | Nov. 12, 2020 |
| Required reporting date | Nov. 12, 2021, midnight |
| Actual reporting date | April 9, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 879 |